Pulmonary Function Trajectories Over 6 Years and Their Determinants in Type 2 Diabetes: The Fremantle Diabetes Study Phase II
Authors' conclusion
Measurement of lung function in type 2 diabetes could help optimize clinical management and improve prognosis, including addressing glycemic control in those with a very low FEV1%pred.
Study context
- Population
- People with T2D in the Fremantle Diabetes Study Phase II with ≥2 biennial FEV1%pred measurements over 6 years; mean age 65.2 years, 45.5% female, median diabetes duration 8.0 yearsof 1,482 potential
- Participants
- 1,074 people
- Exposure
- FEV1%pred trajectory groups
- Outcome
- FEV1%pred trajectory group membership
- Follow-up
- 6 years
Methodological detailscommunity-based observational, group-based trajectory modeling, multinomial regression
- Community-based observational
- Group-based trajectory modeling
- Multinomial regression
Main finding
As reported in the abstract
FEV1%pred trajectory groups (share; baseline FEV1%pred; slope)
FEV1%pred trajectory groups (share; baseline FEV1%pred; slope) · 6 years
Share High 19.5% · Medium 47.7% · Low 25.0% · Very low 7.9%
Slope High 0%/year · Medium −0.32%/year · Low −0.72%/year · Very low −0.68%/year
Observational data: associations, not effects.
Further findings
| Outcome | High | Very low |
|---|---|---|
| Mortality | 6.7% | 22.4% |
Mortality
- Graded increase in mortality from high to very low group
Original publication
Pulmonary Function Trajectories Over 6 Years and Their Determinants in Type 2 Diabetes: The Fremantle Diabetes Study Phase II. Diabetes Care. Published 11 January 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →